TORONTO, Feb. 2 /CNW/ - Biosign Technologies Inc. (TSXV: BIO, "Biosign")
announces the granting of incentive stock options to certain officers,
directors, employees, and consultants of the company.
Subject to TSX Venture Exchange approval, Biosign has today granted
3,983,500 incentive stock options pursuant to the Biosign Stock Option
Plan. These options will be exercisable at prices of $1.50 and $2.25
per share and will expire on January 24, 2016. One million options vest
immediately and the balance over the next 18 months. After today's
option grants, a total of 2,774,650 incentive stock options remain
available under the Stock Option Plan. Additional information about
Biosign can be found in its filings at www.sedar.com.
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key
applications include intelligent systems for noninvasive monitoring of
common health risks associated with blood pressure, glucose, and
medication. The core technology combines measurement, analysis, and
rapid knowledge formation to support health monitoring across global
markets. The UFIT® medical device technology powers quality data
collection and analytics for clinical diagnostics, self-care, wellness,
disease state evaluation & management, and remote patient monitoring.
For more information on Biosign, please visit www.biosign.com
This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in, Biosign's filings with
Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE Biosign Technologies Inc.
For further information:
|Peter Tassiopoulos |
Biosign Technologies Inc.
Phone: (416) 218-9800 ext. 234
|Alan S. Roemer, SVP|
The Trout Group LLC
Phone: 646 378-2900